Goldman Sachs Discloses 4.23M Shares (5.6%) of SpringWorks on Schedule 13G

Rhea-AI Filing Summary

Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC report beneficial ownership of 4,234,033.35 shares of SpringWorks Therapeutics common stock, representing 5.6% of the class. The filing shows the positions are held with shared voting power (4,233,899.35 shares) and shared dispositive power (4,234,021.35 shares), and no sole voting or dispositive power is reported. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a joint filing agreement and identifies Goldman Sachs & Co. LLC as a subsidiary of the parent reporting entity.

Positive

• Material disclosure: The filing transparently reports 4,234,033.35 shares, crossing the 5% threshold and providing market clarity.
• Passive position: The Schedule 13G and certification state the holdings are held in the ordinary course of business and not to influence control.

Negative

• No sole voting or dispositive power: The reporting persons indicate 0 shares of sole voting or dispositive power, limiting direct governance influence.
• Concentrated stake: A single financial group holds 5.6% of the class, which increases ownership concentration even if passive.

Insights

Financial Analyst

TL;DR: Goldman Sachs reports a material passive stake of 5.6% in SpringWorks, disclosed as shared holdings without sole control.

The reported 4.23 million-share position equals 5.6% of SpringWorks' common stock, crossing the 5% reporting threshold and requiring public disclosure. The Schedule 13G presentation and the certification that the holdings are in the ordinary course indicate a passive, non-control position rather than an activist stake. For market participants, this clarifies ownership concentration and the role of a major financial institution as a significant shareholder, but it does not signal an intent to change management or strategy.

Corporate Governance Expert

TL;DR: Reporting shows shared voting and dispositive authority, with no sole control; governance influence appears limited per the filing.

The filing discloses shared voting power and shared dispositive power with zero sole powers, which is material for governance analysis because sole voting authority is not claimed. The statement explicitly affirms the securities are not held to influence control, and the joint filing agreement clarifies coordination between the parent and its subsidiary. These facts suggest the reported position is relevant to ownership concentration but does not reflect an immediate governance change or control intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

SPRINGWORKS THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

85205L107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 85205L107

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,233,899.35
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,234,021.35

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,234,033.35

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 85205L107

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,233,899.35
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,234,021.35

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,234,033.35

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SPRINGWORKS THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 100 WASHINGTON BOULEVARD, STAMFORD, X1, 06902
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 85205L107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Sam Prashanth
Name/Title:	Attorney-in-fact
Date:	07/17/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name: Sam Prashanth
Name/Title:	Attorney-in-fact
Date:	07/17/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of SPRINGWORKS THERAPEUTICS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Sam Prashanth ---------------------------------------- Name: Sam Prashanth Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Sam Prashanth ---------------------------------------- Name: Sam Prashanth Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

Who filed the Schedule 13G for SpringWorks Therapeutics (SWTX)?

The filing was made jointly by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

How many SpringWorks (SWTX) shares does Goldman Sachs report owning?

They report beneficial ownership of 4,234,033.35 shares of common stock.

What percentage of SpringWorks (SWTX) does that stake represent?

The reported holdings represent 5.6% of the outstanding common stock.

Does Goldman Sachs claim sole voting or dispositive power over these shares?

No. The filing shows 0 shares of sole voting power and 0 shares of sole dispositive power, and lists shared powers instead.

Does the Schedule 13G indicate intent to influence control of SpringWorks?

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control.